Credentialing the AI Doctor: The FDA's Blueprint for Generative AI

The FDA is asking the healthcare industry how to regulate generative AI medical devices. We unpack their proposed competency-based approach, which evaluates AI less like software and more like a human medical resident.

Key points

Generative AI requires new regulatory frameworks because it produces variable outputs to similar inputs and can evolve after deployment.The FDA proposes a two-axis framework to assess risk based on device activity (how independently it acts) and the consequences of an incorrect output.A new competency-based premarket evaluation would mirror human clinician credentialing, using robust benchmarking and clinical confirmation.Postmarket monitoring could involve periodic re-benchmarking and shared responsibility across the healthcare ecosystem to catch performance degradation.The FDA suggests voluntary master files for foundation models, allowing developers to share underlying safety data without making it public.

Source: Considerations for the Regulation of Generative AI-Enabled Medical Devices: Discussion Paper and Request for Feedback - U.S. Food and Drug Administration, 2026

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/credentialing-the-ai-doctor-the-fda-s-blueprint-for-generative-ai-944c85